Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. Summary
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
104 103.1 102.3 102.1 101.3 Last
309000 191500 58500 126500 121020 Volume
+1.76% -0.87% -0.78% -0.20% -0.78% Change
Estimated financial data (e)
Sales 2021 1 121 M 176 M 176 M
Net income 2021 -88,6 M -13,9 M -13,9 M
Net cash position 2021 3 133 M 491 M 491 M
P/E ratio 2021 -307x
Yield 2021 -
Sales 2022 1 479 M 232 M 232 M
Net income 2022 -135 M -21,1 M -21,1 M
Net cash position 2022 1 817 M 285 M 285 M
P/E ratio 2022 -207x
Yield 2022 -
Capitalization 49 620 M 6 383 M 7 774 M
EV / Sales 2021 41,5x
EV / Sales 2022 32,3x
Nbr of Employees 1 735
Free-Float 68,5%
More Financials
Company
RemeGen Co Ltd is a China-based company engaged in research, development and commercialization of biological drugs. The Company's clinical-stage drug candidates include telitacicept (RC18) used for the treatment of systemic lupus erythematosus, and disitamab vedotin (RC48) used for the treatment of gastric cancer. 
More about the company
Ratings of RemeGen Co., Ltd.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about REMEGEN CO., LTD.
09/21Seagen Inc. Enters into License Agreement with RemeGen Co., Ltd
CI
09/15China's biotech sector comes of age with big licensing deals, global ambitions
RE
08/23Remegen Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
08/11REMEGEN : Completes Phase II Trial of Berger's Disease Treatment in China; Shares Jump 3%
MT
08/10REMEGEN : Strikes $2.6 Billion Cancer Drug Licensing Deal with Nasdaq-listed Seagen
MT
08/10Announces Preliminary Result of Telitacicept in the Phase II Study to Treat IGA Nephrop..
CI
08/02REMEGEN : Wins Regulatory Nod to Conduct Clinical Trial of Tumor Drug in Australia
MT
07/30RemeGen Co., Ltd. Receives an Ethical Approval from the Human Research Ethics Committee..
CI
07/15REMEGEN : China Accepts RemeGen's New Drug Application for Cancer Medication
MT
07/14Remegen Co., Ltd. Announces That the National Medical Products Administration Has Accep..
CI
06/28REMEGEN : Cancer Drug Secures Breakthrough Therapy Designation in China
MT
06/21REMEGEN : Shanghai Bourse Accepts RemeGen's IPO Application
MT
06/21REMEGEN CO., LTD.(SEHK : 9995) added to FTSE All-World Index
CI
06/09REMEGEN : Drug Granted Marketing Approval
MT
05/17REMEGEN : Announcement regarding h share full circulation listing approval granted by the ..
PU
More news
News in other languages on REMEGEN CO., LTD.

- No features available -

More news
Chart REMEGEN CO., LTD.
Duration : Period :
RemeGen Co., Ltd. Technical Analysis Chart | 9995 | CNE1000048G6 | MarketScreener
Technical analysis trends REMEGEN CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 101,30 CNY
Average target price 115,82 CNY
Spread / Average Target 14,3%
EPS Revisions
Managers and Directors
Jian Min Fang CEO, Executive Director & Chief Scientific Officer
Dao Tian Fu President
Jia Li Chief Financial Officer & Joint Secretary
Weidong Wang Chairman
Ruyi He Executive Director & Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
REMEGEN CO., LTD.6.63%6 433
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992